SCHEMBL2407564

SCHEMBL2407564

CCc1cnc(N(Cc2ccc(C(F)(F)F)cc2)Cc2csc(SC(C)(C)C(=O)O)n2)nc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.42
TP53 P04637 5/20 0.37
LMNA P02545 4/20 0.37
SLC22A12 Q96S37 3/20 0.36
CACNA1H O95180 1/20 0.35
CACNA1B Q00975 1/20 0.35
HTT P42858 2/20 0.34
PPARG P37231 2/20 0.33
PPARD Q03181 1/20 0.33
CASR P41180 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
LIPE Q05469 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412764 0.92 PPARA (0.40) PPARATP53LMNASLC22A12CACNA1H
SCHEMBL2413324 0.90 PPARA (0.39) PPARAPPARD
SCHEMBL12275862 0.88 SLC22A12 (0.38) PPARATP53SLC22A12HTTPPARG
Hydrochloric Acid SCHEMBL2411488 0.88 SLC22A12 (0.38) PPARATP53SLC22A12HTTPPARG
SCHEMBL2412889 0.85 PPARG (0.36) PPARATP53LMNASLC22A12PPARG
SCHEMBL12275253 0.84 NPC1 (0.37) PPARATP53SLC22A12SMN1; SMN2
SCHEMBL2410846 0.84 PPARA (0.37) PPARAPPARD
Hydrochloric Acid SCHEMBL2410518 0.83 NPC1 (0.36) PPARATP53SLC22A12SMN1; SMN2
SCHEMBL2414548 0.82 PPARA (0.34) PPARASLC22A12PPARGPPARD
SCHEMBL2413028 0.82 PPARA (0.35) PPARATP53LMNASLC22A12PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885TP53 2553/4885LMNA 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.